
The NIH on Autoimmune Disease: An Invisible Epidemic
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an
Back in 2019, pre-Covid pandemic, we already saw attractive investment & business opportunities to meet the large and growing need in autoimmune and chronic immuno-inflammatory diseases. Despite being as prevalent as cancer and growing faster, these diseases remain invisible: under-recognized, under-researched and under-served. In particular, multiple medical specialty silos within
A continuation of Part 1. One of our B2B thought leadership interviews with digital health entrepreneurs working to improve the care of chronic conditions. We care particularly about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. This continues our interview with the CEO of Oshi Health, Sam Holliday. Oshi
First 2021 post in our series of B2B thought leadership interviews with visionary digital health entrepreneurs working to improve care of chronic conditions. In keeping with our mission, we particularly care about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. Bonnie and Ellen were happy to finally interview digital
The COVID-19 pandemic and healthcare systems’ responses to it have been the biggest disruptors in digital health’s 30-year history. We hope this will be the biggest disruptor for a few decades to come! Therefore, this is a unique moment of opportunity for digital health. Especially for digital and virtual-first chronic
On GI practice, beta risk, digital health, VBP and chronic care Another in our new series of B2B thought leadership interviews with visionary entrepreneurs applying digital tools to improve care of chronic immunoinflammatory disorders (CID), including autoimmune and autoinflammatory diseases. We were delighted to speak with Dr Lawrence R. Kosinski,
Applying Technology to Empower Patients. 2016’s trends gave us glimmers of towards crossing the autoimmune abyss and achieving the vision of individualized autoimmune care. What was the state of autoimmunity in 2016, that unforgettable year full of positive and negative events? One positive development was increasing awareness of the unmet
See Part 1 for how Bonnie met Bill Conlan pre-CrossBridge and for background on his entrepreneurial track record. That background includes SaaS platforms, analytics and the migration from fee-for-service (FFS) to value-based payments (VBP). Part 1 also lays out the challenges Bill saw for specialty practices in chronic disease management.
Welcome to our B2B Thought Leadership series! We are delighted to start with a 2-part post from our interview with Bill Conlan, founder and CEO of CrossBridge. CrossBridge is a Software as a Service (SaaS) platform using data analytics to bridge care coordination gaps between healthcare payers and specialty provider